RTP Mobile Logo

Saturday, August 6, 2022, 9:00 AM – 4:30 PM Pacific Time (12:00 PM - 7:30 PM Eastern Time)

Recent Advances and Real-World Implications in Medical Oncology: A Daylong Multitumor Educational Symposium in Partnership with the American Oncology Network

A CME/MOC- and NCPD-Accredited Hybrid Event

Event Details

Location
Bellagio Las Vegas
3600 S Las Vegas Blvd
Las Vegas, NV 89109
Hotel Phone: (888) 987-6667

Program Schedule — Pacific Time
9:00 AM – 4:30 PM
Breakfast and lunch buffet to be provided

Meeting Room
Grand Ballroom – Salon 2 (First Floor)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. However, preregistration is advised as seating is limited. See LOCATION tab for instructions on how to secure hotel accommodations.  
 
Faculty Presenting Virtually

Breast Cancer

Harold J Burstein, MD, PhD
Institute Physician, Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas

Genitourinary Cancers

Neeraj Agarwal, MD
Professor of Medicine
Senior Director for Clinical Research Innovation
Huntsman Cancer Institute Presidential
Endowed Chair of Cancer Research
Director
Center of Investigational Therapeutics
Director
Genitourinary Oncology Program
Huntsman Cancer Institute
University of Utah (NCI-CCC)
Salt Lake City, Utah

Sandy Srinivas, MD
Professor of Oncology
Clinical Research Leader, GU Oncology
Stanford University
Stanford, California

Multiple Myeloma

Rafael Fonseca, MD
Chief Innovation Officer
Getz Family Professor of Cancer
Distinguished Mayo Investigator
Mayo Clinic in Arizona
Phoenix, Arizona

Krina Patel, MD, MSc
Associate Professor
Center Medical Director
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Chronic Lymphocytic Leukemia and Lymphomas

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

Craig Moskowitz, MD
Physician in Chief and Interim Deputy Cancer Center Director
Sylvester Comprehensive Cancer Center
Professor of Medicine, Miller School of Medicine
University of Miami Health System
Miami, Florida

Gastrointestinal Cancers

Rutika Mehta, MD, MPH
Assistant Member in the Department of Gastrointestinal Oncology
Moffitt Cancer Center
Assistant Professor in the Department of Oncologic Sciences
University of South Florida
Tampa, Florida

Philip A Philip, MD, PhD, FRCP
Professor of Oncology and Pharmacology
Leader, GI and Neuroendocrine Oncology
Henry Ford Cancer Institute
Wayne State University
Detroit, Michigan

Lung Cancer

Ibiayi Dagogo-Jack, MD
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Suresh S Ramalingam, MD
Professor of Hematology and Medical Oncology
Roberto C Goizueta Chair for Cancer Research
Executive Director, Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Moderator Hosting in Person
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AbbVie Inc, Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Epizyme Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Lilly, Merck, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Puma Biotechnology Inc, Seagen Inc, and Taiho Oncology Inc.

Agenda

Join us on Saturday, August 6th for this daylong multitumor CME-MOC/NCPD-accredited hybrid event.
9:00 AM – 4:30 PM Pacific Time (12:00 PM - 7:30 PM Eastern Time)

Opening Remarks | 9:00 AM – 9:05 AM PT (12:00 PM – 12:05 PM ET)

Module 1
Breast Cancer | 9:05 AM – 10:05 AM PT (12:05 PM – 1:05 PM ET)

  • Feasibility of chemotherapy de-escalation with dual HER2 blockade for patients with localized breast cancer
  • Adjuvant T-DM1 for patients with residual disease after neoadjuvant therapy
  • Neratinib as extended-adjuvant therapy; improvement in rates of CNS recurrence after long-term follow-up in the Phase III ExteNET study
  • Optimizing the use of postadjuvant neratinib; available data with and rationale for a dose-escalation strategy
  • Ongoing clinical trials investigating novel HER2-targeted therapy for HER2-positive localized breast cancer (eg, DESTINY-Breast05, CompassHER2 RD, MARGOT)
  • Published data from the pivotal HER2CLIMB, DESTINY-Breast01 and NALA studies of tucatinib/trastuzumab/capecitabine, trastuzumab deruxtecan (T-DXd) and neratinib/capecitabine, respectively, for HER2-positive metastatic breast cancer (mBC)
  • Integration of tucatinib/trastuzumab/capecitabine, T-DXd and neratinib/capecitabine into therapy for patients with and without brain metastases
  • Updated results from the Phase III DESTINY-Breast03 trial evaluating T-DXd versus T-DM1 for previously treated HER2-positive mBC
  • Findings from the Phase III DESTINY-Breast04 trial evaluating T-DXd versus treatment of physician’s choice for patients with previously treated HER2-low unresectable and/or metastatic breast cancer
  • Ongoing clinical studies evaluating novel HER2-targeted combination strategies for HER2-positive mBC (eg, HER2CLIMB-02, DESTINY-Breast07)
  • Major findings from the Phase III RxPONDER trial evaluating the role of chemotherapy for patients with ER-positive, HER2-negative localized breast cancer with 1 to 3 positive lymph nodes and a 21-gene Recurrence Score® of ≤25
  • Key outcomes observed with abemaciclib added to standard adjuvant hormonal therapy for patients with ER-positive, HER2-negative breast cancer in the Phase III monarchE trial; FDA approval and current role of adjuvant abemaciclib
  • Other ongoing studies evaluating CDK4/6 inhibitors as neoadjuvant or adjuvant therapy
  • Long-term follow-up data with CDK4/6 inhibitors for patients with ER-positive mBC
  • Major research findings with alpelisib/fulvestrant for patients with ER-positive mBC and a PIK3CA mutation
  • Optimal prevention and management strategies for alpelisib-related toxicities
  • Findings from the FAKTION trial evaluating fulvestrant with capivasertib versus fulvestrant with placebo after relapse or progression on an aromatase inhibitor for ER-positive mBC
  • Key outcomes of the Phase III OlympiA trial assessing adjuvant olaparib for patients with germline BRCA1/2 mutations and high-risk, HER2-negative breast cancer; current and potential role of adjuvant olaparib
  • Available data from the Phase III KEYNOTE-522 study of neoadjuvant pembrolizumab combined with chemotherapy and continued as a single agent after surgery for high-risk localized triple-negative breast cancer (TNBC)
  • Phase III data sets evaluating anti-PD-1/PD-L1 antibodies with chemotherapy for patients with previously untreated PD-L1-positive metastatic TNBC (mTNBC)
  • Key research findings guiding the optimal use of PARP inhibitors for patients with mBC
  • Primary results from the Phase III TROPiCS-02 study evaluating sacituzumab govitecan versus treatment of physician’s choice for patients with ER-positive advanced breast cancer
  • Other novel agents under investigation for mTNBC (eg, T-DXd, ladiratuzumab vedotin, datopotamab deruxtecan)

Module 2
Genitourinary Cancers | 10:05 AM – 11:05 AM PT (1:05 PM – 2:05 PM ET)

  • Major efficacy and safety findings with and current clinical role of the oral GnRH antagonist relugolix for men with advanced prostate cancer
  • Key findings from the STAMPEDE platform assessing the addition of abiraterone and prednisolone with or without enzalutamide to androgen deprivation therapy (ADT) for men with high-risk nonmetastatic prostate cancer
  • Long-term efficacy outcomes with enzalutamide, apalutamide or darolutamide for nonmetastatic castration-resistant prostate cancer; implications of differential toxicity profiles for therapeutic selection
  • PEACE-1 trial: Docetaxel with or without abiraterone with or without local radiation therapy for men with de novo metastatic hormone-sensitive prostate cancer (mHSPC); implications for clinical practice
  • Long-term follow-up from Phase III studies supporting the use of enzalutamide and apalutamide for mHSPC
  • Results from the Phase III ARASENS trial demonstrating improved overall survival with darolutamide in combination with docetaxel and ADT for mHSPC; potential clinical significance
  • Efficacy and safety of approved PARP inhibitors (olaparib and rucaparib) in men with metastatic castration-resistant prostate cancer (mCRPC); optimal integration of these agents into management algorithms
  • Efficacy and safety findings from the Phase III PROpel trial comparing olaparib in combination with abiraterone to abiraterone alone as first-line therapy for patients with mCRPC with and without homologous recombination repair (HRR) gene mutations
  • First results of the Phase III MAGNITUDE study of niraparib with abiraterone/prednisone as first-line therapy for patients with mCRPC with and without HRR gene mutations
  • Other ongoing Phase III clinical research evaluating the role of PARP inhibitors with secondary hormonal agents for patients with mCRPC (eg, TALAPRO-2, CASPAR) and mHSPC (eg, TALAPRO-3, AMPLITUDE)
  • Available results from studies investigating the optimal sequencing of cabazitaxel in therapy for mCRPC
  • Impact of the addition of bone-protecting agents during treatment with radium-223 chloride and enzalutamide in the Phase III EORTC-1333-GUCG/PEACE III trial
  • Findings from the Phase III VISION study evaluating 177Lu-PSMA-617 for progressive PSMA-positive mCRPC; recent FDA approval and appropriate integration into clinical practice
  • Three-year follow-up results from the TheraP trial evaluating 177Lu-PSMA-617 versus cabazitaxel for mCRPC progressing after docetaxel
  • Findings from the Phase III KEYNOTE-564 study of adjuvant pembrolizumab for high-risk clear-cell renal cell carcinoma (RCC); recent FDA approval and patient selection
  • Use of nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib for treatment-naïve metastatic RCC (mRCC)
  • FDA approval for lenvatinib/pembrolizumab as first-line therapy for mRCC
  • Results of the Phase III CheckMate 9ER trial of nivolumab/cabozantinib for previously untreated mRCC; FDA approval and optimal integration into current first-line treatment algorithms
  • Rational sequencing of available therapies for RCC that progresses on front-line treatment; patient-specific factors in decision-making in this setting
  • FDA approval and optimal clinical role of tivozanib for patients with mRCC
  • FDA approval, ongoing evaluation and efficacy of belzutifan in patients with von Hippel-Lindau disease-associated RCC
  • Selection of appropriate patients with high-risk non-muscle-invasive urothelial bladder cancer (UBC) for pembrolizumab therapy
  • Results of the Phase III CheckMate 274 trial comparing nivolumab to placebo after surgery for patients with high-risk muscle-invasive UBC; recent FDA approval and optimal integration into practice
  • Efficacy, tolerability and ongoing investigation of TAR-200 (intravesical gemcitabine drug delivery system) for muscle-invasive UBC
  • Findings from the Phase II TRUCE-02 trial of tislelizumab combined with nab paclitaxel for high-risk non-muscle-invasive UBC
  • Current clinical role of atezolizumab and pembrolizumab as first-line treatment for metastatic UBC (mUBC); importance of chemotherapy eligibility and PD-L1 status in patient selection for this strategy
  • Appropriate incorporation of first-line maintenance avelumab into clinical care
  • Activity of enfortumab vedotin in patients with progressive mUBC; FDA-approved indication and optimal integration into the treatment paradigm
  • Efficacy and potential clinical role of enfortumab vedotin/pembrolizumab for patients with previously untreated mUBC
  • Clinical role of erdafitinib for patients with mUBC and FGFR3 or FGFR2 genetic alterations
  • Findings from the Phase II TROPHY U-01 trial leading to the FDA approval of sacituzumab govitecan for patients with progressive mUBC; optimal integration into clinical management
  • FDA breakthrough therapy designation for disitamab vedotin for progressive HER2-overexpressing mUBC

Break | 11:05 AM – 11:20 AM PT (2:05 PM – 2:20 PM ET)

Module 3
Multiple Myeloma (MM) | 11:20 AM – 12:20 PM PT (2:20 PM – 3:20 PM ET)

  • Current utility of carfilzomib as a component of up-front therapy
  • Published research findings with daratumumab-containing front-line regimens for newly diagnosed MM; role for patients who are eligible and ineligible for transplant
  • Recently presented findings from the Phase III DETERMINATION trial of RVD (lenalidomide/bortezomib/dexamethasone), with or without autologous stem cell transplant, and maintenance lenalidomide to disease progression for patients with newly diagnosed MM; implications for clinical practice
  • Current role of minimal residual disease (MRD) assessment in MM decision-making; optimal platforms
  • Approach to maintenance therapy for transplant-eligible and ineligible patients, including those who have received daratumumab-based induction therapy
  • Available data with and current indications, if any, for ixazomib in the induction and maintenance settings
  • FDA approval of idecabtagene vicleucel and updated results from the pivotal Phase II KarMMa trial evaluating this agent for patients with relapsed/refractory (R/R) MM
  • Available data from the CARTITUDE-1 and CARTITUDE-2 studies of ciltacabtagene autoleucel for pretreated MM; recent FDA approval and clinical role
  • Early data with and ongoing research evaluating other chimeric antigen receptor (CAR) T-cell platforms and strategies for MM
  • Incidence, severity and management of class-effect toxicities observed with B-cell maturation antigen (BCMA)-targeted CAR T-cell therapies
  • Published Phase III research with isatuximab for R/R MM (eg, ICARIA-MM, IKEMA trials)
  • Results from the Phase III BOSTON trial evaluating selinexor in combination with bortezomib/dexamethasone for R/R MM; FDA approval and patient selection
  • Ongoing studies of selinexor in combination with other agents and in earlier lines of therapy
  • Efficacy and safety results from the Phase II DREAMM-2 study leading to the FDA approval of belantamab mafodotin monotherapy for patients with R/R MM; incorporation into routine practice
  • Monitoring for and management of ocular and other toxicities with belantamab mafodotin
  • Available data with and ongoing evaluation of belantamab mafodotin in combination with other systemic therapies
  • Mechanism of action of and available safety and efficacy data with BCMA-directed (eg, teclistamab, elranatamab) and non-BCMA-directed (eg, talquetamab, cevostamab) bispecific antibodies for R/R MM
  • Biologic rationale for targeting Bcl-2 in MM; published data with and ongoing investigation of venetoclax-based therapy for patients with t(11;14) MM or Bcl-2 overexpression
  • Activity and safety observed with the cereblon E3 ligase modulators iberdomide and CC-92480 in patients with heavily pretreated MM
  • Other promising novel agents and strategies under investigation for MM

Lunch Break | 12:20 PM – 12:55 PM PT (3:20 PM – 3:55 PM ET)

Module 4
Chronic Lymphocytic Leukemia (CLL) and Lymphomas | 12:55 PM – 1:55 PM PT (3:55 PM – 4:55 PM ET)

  • Pivotal data sets with Bruton tyrosine kinase (BTK) inhibitor-based therapy for treatment-naïve CLL
  • Implications for therapeutic decision-making of results from the Phase III ELEVATE-RR study evaluating acalabrutinib versus ibrutinib for previously treated high-risk CLL
  • Results from the Phase III ALPINE and SEQUOIA trials evaluating zanubrutinib for CLL
  • Key data sets informing the optimal use of venetoclax for newly diagnosed CLL
  • Current role and optimal platforms for MRD assessment for patients with CLL
  • Results from the Phase III GLOW trial evaluating first-line ibrutinib/venetoclax versus chlorambucil/obinutuzumab
  • Key factors guiding the selection of therapy for patients with disease progression on first-line treatment
  • Current and future role of PI3 kinase (PI3K) inhibition in the CLL treatment paradigm
  • Efficacy and safety of pirtobrutinib in the Phase I/II BRUIN study; ongoing investigation and potential clinical role of CD19-directed CAR T-cell therapy for patients with R/R CLL
  • Integration of obinutuzumab into current therapeutic algorithms for treatment-naïve and R/R follicular lymphoma (FL)
  • Lenalidomide/rituximab in the management of newly diagnosed and R/R FL
  • Key findings from the Phase III CHRONOS-3 trial of copanlisib in combination with rituximab for patients with R/R FL
  • Available data from the Phase IIb UNITY-NHL trial evaluating umbralisib for patients with R/R FL; FDA approval of umbralisib
  • Results from the Phase II CITADEL-203 study evaluating the next-generation PI3K inhibitor parsaclisib for R/R FL
  • Optimal integration of tazemetostat into the management of previously treated FL with and without EZH2 mutations
  • Available data with and FDA approvals of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tis-cel) for R/R FL
  • Early-phase data with and potential clinical role of investigational bispecific antibodies (eg, mosunetuzumab, glofitamab, epcoritamab) for R/R FL
  • Key results from the Phase III POLARIX study comparing polatuzumab vedotin in combination with chemotherapy to R-CHOP for previously untreated diffuse large B-cell lymphoma (DLBCL); implications for clinical practice
  • Published research findings with polatuzumab vedotin in combination with bendamustine/rituximab (BR) for R/R DLBCL
  • Available data with and FDA approval of loncastuximab tesirine
  • Key data leading to the FDA approval of tafasitamab/lenalidomide for R/R DLBCL
  • Long-term data with axi-cel, tis-cel and lisocabtagene maraleucel (liso-cel) for R/R DLBCL
  • Phase III data with CAR T-cell therapy as second-line treatment for DLBCL
  • Research database supporting the FDA approvals of ibrutinib, acalabrutinib and zanubrutinib for R/R mantle cell lymphoma (MCL); key factors in the choice of BTK inhibitor and practical use of these agents
  • Primary results from the Phase III SHINE study of ibrutinib/BR and maintenance rituximab as first-line treatment for older patients with MCL
  • Activity and safety data with and ongoing Phase III investigations of novel agents (eg, lenalidomide, BTK inhibitors) for previously untreated MCL
  • Venetoclax alone or combined with other agents (eg, BTK inhibitors) for MCL
  • Key efficacy and safety data with approved (brexucabtagene autoleucel) and investigational (liso-cel) CAR T-cell platforms in therapy for MCL
  • Efficacy and safety observed with pirtobrutinib in patients with MCL in the Phase I/II BRUIN trial
  • Long-term progression-free survival follow-up and prespecified overall survival analysis from the Phase III ECHELON-1 trial of first-line brentuximab vedotin (BV) and AVD (doxorubicin/vinblastine/dacarbazine) for advanced classical Hodgkin lymphoma
  • Early findings with BV combined with chemotherapy for early-stage unfavorable-risk Hodgkin lymphoma
  • Current role of BV for older patients with newly diagnosed Hodgkin lymphoma
  • Potential role of BV alone or in combination with immune checkpoint inhibition as a bridge to transplant
  • Key outcomes from the Phase III KEYNOTE-204 trial evaluating pembrolizumab versus BV for patients with R/R Hodgkin lymphoma; implications for clinical practice

Module 5
Gastrointestinal Cancers | 1:55 PM – 2:55 PM PT (4:55 PM – 5:55 PM ET)

  • Appropriate use of encorafenib/cetuximab for patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutations; available results and ongoing investigation with earlier use of BRAF-targeted therapy
  • Immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient mCRC
  • Incorporation of regorafenib and TAS-102 in the treatment of multiregimen-refractory mCRC
  • Available data with and potential role of TAS-102 in combination with other systemic agents or in earlier disease stages; NCCN guideline inclusion of TAS-102/bevacizumab
  • Updated results from the DESTINY-CRC01 study of T-DXd for HER2-expressing mCRC
  • Early results with and ongoing evaluation of the KRAS G12C inhibitor sotorasib for mCRC with a KRAS G12C mutation
  • Phase III data (eg, from the CheckMate 649, CheckMate 648 and KEYNOTE-590 trials) demonstrating the efficacy and safety of first-line checkpoint inhibitor-containing regimens for advanced gastric, gastroesophageal junction (GEJ) and esophageal cancer
  • Available Phase III research findings (eg, from the ORIENT-16, ORIENT-15 and JUPITER-06 trials) with investigational anti-PD-1 antibodies in combination with chemotherapy as first-line treatment for advanced gastroesophageal tumors; potential clinical role
  • Available data from the Phase III CheckMate 577 study of adjuvant nivolumab for resected esophageal or GEJ cancer
  • Optimal placement of ramucirumab in current clinical algorithms for metastatic gastric/GEJ cancer; ongoing investigation of ramucirumab-containing combination regimens
  • Use of TAS-102 in the management of heavily pretreated metastatic gastric/GEJ cancer
  • Principal outcomes in the Phase III KEYNOTE-811 trial evaluating first-line pembrolizumab/ trastuzumab/chemotherapy for metastatic HER2-positive gastric/GEJ adenocarcinoma
  • DESTINY-Gastric01 and DESTINY-Gastric02 trials of T-DXd for progressive HER2-positive gastric/GEJ cancer
  • Key findings from the Phase II FIGHT trial of first-line bemarituzumab/chemotherapy for FGFR2b-positive metastatic gastric/GEJ cancer
  • Key data with first-line atezolizumab/bevacizumab for unresectable hepatocellular carcinoma (HCC)
  • Recently presented findings from the Phase III HIMALAYA trial evaluating first-line durvalumab/tremelimumab for unresectable HCC
  • Results from the Phase III COSMIC-312 study evaluating first-line cabozantinib/atezolizumab versus sorafenib for metastatic HCC
  • Roles of sorafenib and lenvatinib in first-line therapy for advanced HCC
  • Long-term outcomes with anti-angiogenic agents (eg, regorafenib, cabozantinib, ramucirumab) for progressive HCC
  • Results from the TOPAZ-1 trial of first-line durvalumab with chemotherapy for advanced biliary tract cancers
  • Outcomes from the Phase II HERB study of T-DXd for patients with HER2-expressing unresectable or recurrent biliary tract cancer
  • FDA approvals of pemigatinib and infigratinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement
  • Results with futibatinib for intrahepatic cholangiocarcinoma with an FGFR2 fusion/rearrangement from the FOENIX-CCA2 trial
  • FDA approval of ivosidenib for patients with previously treated cholangiocarcinoma with an IDH1 mutation; implications for current practice
  • Selection of neoadjuvant and adjuvant systemic therapy for patients with localized pancreatic adenocarcinoma (PAD)
  • Optimal selection of first- and later-line treatment for patients with metastatic PAD
  • Patient selection for and practical integration of nal-IRI for relapsed metastatic PAD; early front-line activity observed with NALIRIFOX, the combination of nal-IRI, 5-FU/leucovorin and oxaliplatin
  • Key efficacy and safety findings with and optimal integration of olaparib as maintenance therapy after first-line chemotherapy for patients with metastatic PAD with a germline BRCA mutation

Break | 2:55 PM – 3:10 PM PT (5:55 PM – 6:10 PM ET)

Module 6
Lung Cancer | 3:10 PM – 4:10 PM PT (6:10 PM – 7:10 PM ET)

  • FDA approval of adjuvant osimertinib; patient selection and optimal incorporation into clinical care
  • Optimal first-line treatment for metastatic non-small cell lung cancer (NSCLC) with EGFR tumor mutations
  • Available data with and ongoing evaluation of the novel HER3-directed antibody-drug conjugate patritumab deruxtecan for metastatic EGFR tyrosine kinase inhibitor-resistant NSCLC
  • Key data informing the FDA approvals of mobocertinib and amivantamab for patients with EGFR exon 20 insertion mutations who have experienced disease progression on first-line chemotherapy
  • Activity and tolerability of lazertinib and amivantamab in the CHRYSALIS-2 trial for patients with NSCLC with EGFR mutations after disease progression on osimertinib and platinum-based chemotherapy
  • Available data informing the use of alectinib, brigatinib or lorlatinib as first-line therapy for patients with NSCLC and ALK rearrangements
  • Principal efficacy and safety results with entrectinib for NSCLC with a ROS1 rearrangement; appropriate integration into clinical practice
  • Published data with and ongoing trials of other “next-generation” ROS1 inhibitors (eg, repotrectinib, larotrectinib, lorlatinib, ceritinib)
  • Available data with selpercatinib and with pralsetinib for patients with advanced NSCLC and RET alterations; optimal integration into clinical practice
  • Current clinical roles of capmatinib and tepotinib for NSCLC with a MET exon 14 mutation
  • Principal efficacy and safety findings with sotorasib for pretreated NSCLC with a KRAS G12C mutation
  • Key outcomes from the Phase II DESTINY-Lung01 study evaluating T-DXd in NSCLC with a HER2 mutation; FDA priority review designation and potential nonresearch role
  • Results from the Phase III CheckMate 816 trial evaluating neoadjuvant nivolumab in combination with chemotherapy for resectable NSCLC
  • FDA approval and current clinical role of adjuvant atezolizumab; principal findings from the Phase III IMpower010 trial evaluating atezolizumab after adjuvant chemotherapy for patients with completely resected NSCLC
  • Long-term data from the Phase III PACIFIC trial of consolidation durvalumab after chemoradiation therapy for unresectable Stage III NSCLC
  • Other ongoing and planned clinical trials of immune checkpoint inhibitors for patients with nonmetastatic NSCLC
  • Clinical trial database supporting the FDA approvals of pembrolizumab and atezolizumab as monotherapy and combined with chemotherapy as first-line treatment
  • Available efficacy and safety data with cemiplimab as monotherapy and in combination with platinum-based chemotherapy as first-line treatment for NSCLC
  • Phase III clinical trial results with first-line nivolumab/ipilimumab with and without chemotherapy (CheckMate 227, CheckMate 9LA); patient selection and optimal integration into practice
  • POSEIDON: A Phase III trial evaluating durvalumab or durvalumab/tremelimumab in combination with platinum-based chemotherapy versus chemotherapy alone as first-line therapy
  • Efficacy and safety observed with the anti-PD-1 monoclonal antibody tislelizumab in patients with advanced NSCLC; ongoing evaluation
  • Ongoing investigation of the TROP2-directed antibody-drug conjugate datopotamab deruxtecan for patients with progressive metastatic NSCLC
  • Key efficacy and safety findings with chemotherapy in combination with atezolizumab or durvalumab for previously untreated extensive-stage small cell lung cancer (SCLC)
  • Available data with and current clinical role of lurbinectedin for patients with SCLC who experience disease progression after platinum-based therapy
  • FDA approval of trilaciclib; optimal incorporation into routine practice as a means to preserve bone marrow function during chemotherapy in patients with extensive-stage SCLC

Closing Remarks | 4:10 PM – 4:30 PM PT (7:10 PM – 7:30 PM ET)

MEETING ADJOURNS | 4:30 PM PT (7:30 PM ET)

CE Information

Target Audience
This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, gastrointestinal, genitourinary, lung and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing clinical trials in breast, gastrointestinal, genitourinary, lung and select hematologic cancers, and refer appropriate patients for participation.
  • Incorporate clinical characteristics, logistical factors, tumor biomarkers and single and multigene signatures in individualizing the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer treatment algorithms in light of new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

Accreditation Statements
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

NCPD Credit Designation Statements
This educational activity for 6 contact hours is provided by Research To Practice.

This activity is awarded 6 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must return a completed Educational Assessment and Credit Form for the modules they attend. The credit form links will be emailed to participants within 5 business days of the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice, ACCME or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Research To Practice CME/NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Epizyme Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Lilly, Merck, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Puma Biotechnology Inc, Seagen Inc, and Taiho Oncology Inc.

Location

Bellagio Las Vegas
3600 S Las Vegas Blvd
Las Vegas, NV 89109
Hotel Phone: (888) 987-6667

Meeting Room
Grand Ballroom – Salon 2 (First Floor)

Please be sure to contact the Bellagio Las Vegas directly to book accommodations in the American Oncology Network (AON) Clinical Summit room block.

Directions:
The Bellagio Las Vegas is the main venue for the 2022 AON Clinical Summit.

 

Registration

This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

​ ​
IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
​ ​
STANDBY Registration other/industry professionals*

We will inform you if your in-person registration request has been approved.

IN-PERSON StandBy Registration »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration

We will stream this event on Zoom. After registering for the webcast, you will receive a separate confirmation from Zoom with the viewing instructions.

LIVE WEBCAST Registration »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

​ Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

​ Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.